Shengnuo Biotech (688117): Deeply involved in the field of peptides, the expansion of multiple business segments is imminent
Huafu Securities released a research report on April 24 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating, and the target price was 35.7 yuan. The main reasons for the rating include: 1) GLP-1 is driving the expansion of the peptide mark
Shengnuo Biotech (688117) Company Information Update Report: Profit Side Flexibility Is Gradually Unleashed, New Production Capacity Is About to Be Implemented to Break Through Supply Bottlenecks
Open Source Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating. The main reasons for the rating include: 1) the gradual release of profit-side flexibility, and the overall steady developme
Huafu Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) a purchase rating, and the target price was 35.7 yuan. The main reasons for the rating include: 1) incident: the company released the 2023 annual rep
Shengnuo Biotech (688117): Steady performance growth is expected to be implemented in new production capacity to drive faster performance
Guojin Securities released a research report on April 23 stating that it gave Shengnuo Biotech (688117.SH) an increase rating. The main reasons for the rating include: 1) the comprehensive peptide layout consolidates the first-mover advantage, and the lay
Shengnuo Biotech (688117): Comprehensive peptide layout consolidates first-mover advantage and accelerates production expansion
Shengnuo Biotech (688117): The trend of leading companies in peptide APIs is accelerating their performance is clear
Shengnuo Biotech (688117) Company's First Coverage Report: Focusing on the implementation of new production capacity in the entire peptide industry chain to open up room for growth
Shengnuo Biotech (688117): The company's development enters the fast track under short-term pressure on Q3 performance and the expected implementation of new production capacity
Shengnuo Biotech (688117): Promoting R&D, expanding production capacity, promising growth in the peptide field
Shengnuo Biotech (688117): A leader in solid-phase peptide synthesis, CDMO business is growing
Shengnuo Biotech (688117) 2023 Interim Report Review: Business is developing steadily, and new production capacity is expected to be implemented by the end of the year
Shengnuo Biotech (688117): Expected to achieve rapid growth under new production capacity
Shengnuo Biotech (688117): Performance accelerates, leading peptide track development enters the fast track
No Data